P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension
Silvio Danese(IRCCS Ospedale San Raffaele), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Ramesh Arasaradnam(University Hospital Coventry), Rupert W. Leong(The University of Sydney), Yiying Zhou(Janssen (United States)), H Zhang(Janssen (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), Chris O’Brien(Neurocrine Biosciences (United States)), Ellen Scherl(NewYork–Presbyterian Hospital), Jewel Johanns(Johnson & Johnson (United States)), Remo Panaccione(University of Calgary)
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k